The iPLEDGE program is a risk management distribution program mandated by the U.S. Food and Drug Administration (FDA) for isotretinoin, marketed as Absorica, Claravis, Amnesteem, Myorisan, and Zenatane, and sometimes referred to by its former brand name, Accutane. Isotretinoin is a prescription medication that is highly effective in treating severe acne and moderate acne that doesn't respond to other treatments, however carries a high risk of causing severe birth defects if taken during pregnancy ("see Teratogenicity of isoretinoin"). The goals of the iPLEDGE REMS (risk evaluation and mitigation strategy) Program are to prevent fetal exposure to isotretinoin and to inform prescribers, pharmacists, and patients about isotretinoin's serious risks and safe-use conditions.